



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/531,874	04/19/2005	Ryuji Ueno	Q87423	5640
23373 7590 10/22/2010 SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, N.W. SUITE 800 WASHINGTON, DC 20037				
EXAMINER POLANSKY, GREGG				
ART UNIT		PAPER NUMBER		
1614				
NOTIFICATION DATE		DELIVERY MODE		
10/22/2010		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

sughrue@sughrue.com
PPROCESSING@SUGHRUE.COM
USPTO@SUGHRUE.COM

Office Action Summary

Application No.

10/531,874

Applicant(s)

UENO, RYUJI

Examiner

GREGG POLANSKY

Art Unit

1614

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 August 2010.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☐ Claim(s) 1,5,7,11-13,21 and 24-26 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,5,7,11-13,21,24 and 25 is/are rejected.
- 7) ☒ Claim(s) 26 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB06)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ ~~Notes of Informal Patent Application~~
- 6) ☐ Other: _____

DETAILED ACTION

Status of Claims

1. Applicant's response, filed 8/09/2010, to the Office Action mailed 5/07/2010 is acknowledged.
2. Applicant's arguments have been fully considered. Rejections and/or objections not reiterated from previous Office actions are hereby withdrawn. The following rejections and objections constitute the complete set presently being applied to the instant application.
3. Claims 1, 5, 7, 11-13, 21 and 24-26 are pending and presently under consideration.
4. In the previous Office Action Claims 11 and 24 were objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Further, Claim 25 was deemed to be allowable. However, Applicant's amendments to Claims 1, 11, 24, and 25 have resulted in the following rejections being applied to those claims.

Claim Objections

5. Claim 26 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claim Rejections - 35 USC § 112

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. Claims 1, 5, 7, 11-13, 21, and 24 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1 and 21 recite the "A" substituent of formula (II) "is $-\text{CH}_3$, or $-\text{CH}_2\text{OH}$, $-\text{COCH}_2\text{OH}$, $-\text{COOH}$ or a salt, **ether**, ester or amide thereof [emphasis added]." An ether is an oxygen atom connected to two alkyl or aryl groups, having the general formula $\text{R}-\text{O}-\text{R}$. It is unclear as to what an ether of the $-\text{COOH}$ moiety is.

8. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 25 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claims contain subject matter that was not described in the Specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention. This is a Written Description rejection.

Claim 25 recites "a compound which is 13,14-dihydro-15-keto-16,16-difluoro PGE_1 or a salt, **ether, ester or amide** thereof" (emphasis added). The Specification recites an ether, ester or amide of $-\text{COOH}$ when substituent A of formula (II) is $-\text{COOH}$.

There is insufficient written basis in the Specification for an ether, ester or amide at any other position in formula (II).

Regarding the requirement for adequate written description of chemical entities, Applicant's attention is directed to MPEP §2163. In particular, *Regents of the University of California v. Eli Lilly & Co.*, 119 F.3d 1559, 1568 (Fed. Cir. 1997), *cert denied*, 523 U.S. 1089, 118 S. Ct. 1548 (1998), holds that an adequate written description requires a precise definition, such as by structure, formula, chemical name, or physical properties, "not a mere wish or plan for obtaining the claimed chemical invention." *Elli Lilly*, 119 F.3d at 1566. The Federal Circuit has adopted the standard set forth in the Patent and Trademark Office ("PTO") Guidelines for Examination of Patent Applications under the 35 U.S.C. 112.1 "Written Description" Requirement ("Guidelines"), 66 Fed. Reg. 1099 (Jan. 5, 2001), which state that the written description requirement can be met by "showing that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics," including, *inter alia*, "functional characteristics when coupled with a known or disclosed correlation between function and structure..." *Enzo Biochem, Inc. v. Gen-Probe Inc.*, 296 F.3d 316, 1324-25 (Fed. Cir. 2002) (quoting *Guidelines*, 66 Fed. Reg. At 1106 (emphasis added)). Moreover, although *Elli Lilly* and *Enzo* were decided within the factual context of DNA sequences, this does not preclude extending the reasoning of those cases to chemical structures in general. *Univ. of Rochester v. G.D. Searle & Co.*, 249 Supp. 2d 216, 225 (W.D.N.Y. 2003).

Applicant has failed to provide any structural characteristics, chemical formula, name(s) or physical properties of ethers, esters or amides of 13,14-dihydro-15-keto-

16,16-difluoro PGE₁, aside from an ether, ester or amide of –COOH when substituent A of formula (II) is –COOH.

9. Claims 1, 5, 7, 11-13, 21, 24, and 25 are rejected under 35 U.S.C. 112, first paragraph, because the Specification, while being enabling for reducing the weight of obese patients by the administration of a 15-keto-16-mono or dihalogen prostaglandin E₁ (PGE₁) compound, a salt thereof, or an ester or amide of the α chain terminal carboxylic acid (see page 3, formula (A) for identification of the PG α chain), it does not reasonably provide enablement for reducing the weight of obese patients by the administration of multitude of prostaglandin compounds as defined by the rejected claims. The Specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. This is a Scope of Enablement rejection.

The factors to be considered in determining whether a disclosure meets the enablement requirements of 35 U.S.C. 112, first paragraph, have been described in *In re Wands*, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir., 1988). The court in *Wands* states, “Enablement is not precluded by the necessity for some experimentation, such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is ‘undue’, not ‘experimentation’” (*Wands*, 8 USPQ2d 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. “Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations” (*Wands*, 8

USPQ2d 1404). Among these factors are: (1) the nature of the invention; (2) the breadth of the claims; (3) the state of the prior art; (4) the predictability or unpredictability of the art; (5) the relative skill of those in the art; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary.

While all of these factors are considered, a sufficient amount for a *prima facie* case is discussed below.


(1) The nature of the invention and (2) the breadth of the claims:

The instant claims are drawn to a method for treating obesity in a subject in need of reduction of body weight, or a method of reducing body weight in a subject in need of treatment for obesity, by administering an effective amount of a "15-keto-16-mono or dihalogen *prostaglandin E₁ compound*" defined by formula (II) of amended claims 1 and 21. Prior to the present claim amendments, Claim 1 was drawn to a method of treatment comprising administering an effective amount of a *prostaglandin compound* as shown by instant formula (I). Claim 11 was drawn to the method of Claim 1, wherein said prostaglandin compound is a 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E₁ compound or 13,14-dihydro-15-keto-16,16-difluoro-18-methyl prostaglandin E₁ compound. 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E₁ and 13,14-dihydro-15-keto-16,16-difluoro-18-methyl prostaglandin E₁ were interpreted as **specific PGE₁ species** of formula (I) in Claim 1. Similarly, the compounds which were recited by Claims 23 and 24 (of the previous claims set) were interpreted as specific PGE₁ species of formula (I). Instant Claims 11 and 24

Art Unit: 1614


as presently amended are quite broad because of the formula (II) definition of PGE₁.

The number of compounds defined by formula (II) is very large. The chemical structure of compounds defined by the claims is quite varied. For example, the compound of Claim 26 (13,14-dihydro-15-keto-16,16-difluoro-PGE₁), which can be defined by formula (II) of Claim 1, has the following structure ("Structure 1"):




Art Unit: 1614

A compound which can be defined by formula (II) of Claims 1 and 21 has the following structure ("Structure 2"):



A compound which can be defined by dependent Claims 11 and 24 is ("Structure 3"):



(3) *The state of the prior art:*

In arguments presented by Applicants (filed 2/16/2010), Applicants pointed out that the disclosure by Ueno et al. (U.S. Patent No. 5,234,954; previously cited) shows that administration of the compound 13,14-dihydro-15-keto-16-fluoro-PGE₂ to rats

does not reduce the body weight of the rats. See columns 17 and 18, including Table 1.

(4) *The predictability or unpredictability of the art and (5) the relative skill of those in the art:*

The relative skill of those in the art of pharmacology and medicine and the unpredictability of the pharmacological and biological arts are very high. In fact, the courts have made a distinction between mechanical elements, which function the same in different circumstances, yielding predictable results, and chemical and biological compounds, which often react unpredictably under different circumstances. *Nationwide Chem. Corp. v. Wright*, 458 F. supp. 828, 839, 192 USPQ 95, 105(M.D. Fla. 1976); *Aff'd* 584 F.2d 714, 200 USPQ 257 (5th Cir. 1978); *In re Fischer*, 427 F.2d 833, 839, 166 USPQ 10, 24(CCPA 1970). Thus, the physiological activity of a chemical or biological compound is considered to be an unpredictable art.

(6) *The amount of direction or guidance presented and (7) the presence or absence of working examples:*

The Specification has provided guidance and a working example for a method of reducing body weight in humans by the oral administration of a single prostaglandin compound, 13,14-dihydro-15-keto-16,16-difluoro-PGE₁. This compound differs from the compound of Ueno et al. (i.e., 13,14-dihydro-15-keto-16-fluoro-PGE₂; which shows no effect on body weight when administered to rats, *supra*) by the presence of a second fluorine at position 16, and the substitution of a single bond for a double

bond between carbons 5 and 6 (i.e., the compound of Ueno et al. is a PGE₂ prostaglandin instead of a PGE₁ prostaglandin).

One of skill in the art would not reasonable expect compounds of encompassing the full breadth of the claims, such as, for example, Structures 2 or 3 (*supra*) to have any physiological activity similar to the instantly claimed compound, 13,14-dihydro-15-keto-16,16-difluoro-PGE₁ (Structure 1, *supra*); especially when one considers that the comparatively minor change in structures between the instant compound, 13,14-dihydro-15-keto-16,16-difluoro-PGE₁, and the compound, 13,14-dihydro-15-keto-16-fluoro-PGE₂, disclosed by Ueno et al., results in the loss of weight reduction when administered to subjects.

(8) The quantity of experimentation necessary:

The amount of guidance or direction needed to enable the invention is inversely related to the degree of predictability in the art. *In re Fisher*, 839, 166 USPQ 24. Thus, although a single embodiment may provide broad enablement in cases involving predictable factors, such as mechanical or electrical elements, in cases involving unpredictable factors, such as most chemical reactions and physiological activity, more teaching or guidance is required. *In re Fisher*, 427 F.2d 839, 166 USPQ 24; *Ex Parte Hitzeman*, 9 USPQ 2d 1823. For example, the Federal Circuit determined that, given the unpredictability of the physiological activity of RNA viruses, a specification requires more than a general description and a single embodiment to provide an enabling disclosure for a method of protecting an organism against RNA viruses. *In re Wright*, 999 F.2d 1562-63, 27 USPQ2d 1575.

The Office maintains a very high standard of enablement for claims drawn to methods of prevention. Considering the factors as discussed above, especially the "breadth of the claims", "sufficient working examples", "the level of skill in the art", "the relative skill and the unpredictability in the pharmaceutical art", and the chemical nature of the invention, one of skill in the art would have to undergo an undue amount of experimentation to use the claimed compounds for the claimed methods.

Conclusion

10. Claims 1, 3-10, 12, 13, 18, 19, 21, 24 and 25 are rejected.
11. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GREGG POLANSKY whose telephone number is (571)272-9070. The examiner can normally be reached on Mon-Thur 9:30 A.M. - 7:00 P.M. EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin H. Marschel can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Gregg Polansky/
Examiner, Art Unit 1614

/James D Anderson/
Primary Examiner, Art Unit 1614